VCC Adult Trials: LYMPHOMA
Recurrent B-Cell Lymphoma
Protocol PCYC-04753: Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma.
Primary Investigator: Barbara Grant, M.D.
Contact: Karen Lepuschenko, (802) 656-9924
Diffuse Large B-Cell Lymphoma
RAD001N 2301 Novartis: A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab chemotherapy.
Primary Investigator: Barbara Grant, M.D.
Contact: Karen Lepuschenko, (802) 656-9924
Relapsed/Refractory Mantle Cell Lymphoma
Protocol CALGB 50501: A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (Revlimid, CC-5013) (NSC #703813) For Relapsed/Refractory Mantle Cell Lymphoma.
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926
Untreated Follicular Non-Hodgkins Lymphoma
Protocol CALGB 50701: A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #101241) plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926
Mantle Cell Lymphoma
Protocol CALGB 50403: A Randomized Phase II Trial of Maintenance vs. Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma.
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926
Recurrent Follicular Non-Hodgkins Lymphoma
Protocol CALGB 50401: A Randomized Phase II Trial of Rituximab vs. Lenalidomide (Revlimid, CC-5013) (IND #73034) vs. Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) after Relapse from a Rituximab-Containing Combination Regimen.
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926
Diffuse Large B-Cell Lymphoma
Protocol CALGB 50303: Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas.
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926
Primary CNS Lymphoma
Protocol CALGB 50202: Intensive Chemotherapy and Immunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926.
Burkitts Lymphoma/Leukemia
Protocol CALGB 10002: A Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with GCSF Support Support in Previously Untreated Patients with Burkitts/Lymphoma/Leukemia.
Primary Investigator: Barbara Grant, M.D.
Contact: Jane Walsh, (802) 656-9926.
